| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/15/2004 | US20040071658 Vaccine immunotherapy for immune suppressed patients |
| 04/15/2004 | US20040071657 Drawing to target site using chemokine, cytokine and/or somatostatin receptor agonist localization factors |
| 04/15/2004 | US20040071656 Modulation of heat-shock-protein-based immunotherapies |
| 04/15/2004 | US20040071655 Binding agent |
| 04/15/2004 | US20040071654 Delivering labile agents; buffering effect; transfecting nucleic acids; nontoxic |
| 04/15/2004 | US20040071650 Reduced side effects |
| 04/15/2004 | US20040071636 Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases |
| 04/15/2004 | US20040070005 Compact high voltage ESD protection diode |
| 04/15/2004 | DE4325927B4 Taxol enthaltender Medikamentierungskit Taxol-containing Medikamentierungskit |
| 04/15/2004 | DE10246125A1 Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren Concentrate of factor VIII: C-containing von Willebrand factor and the associated method |
| 04/15/2004 | CA2836959A1 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| 04/15/2004 | CA2509526A1 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| 04/15/2004 | CA2501958A1 Polynucleotides and polypeptides derived from lactobacillus rhamnosus hn001 |
| 04/15/2004 | CA2500962A1 Uses of human zven proteins and polynucleotides |
| 04/15/2004 | CA2500904A1 Composition containing eosinophil cationic protein |
| 04/15/2004 | CA2500897A1 Long-acting gonadotropin-releasing hormone analogs and methods of use thereof |
| 04/15/2004 | CA2500833A1 Tumor targeting agents and uses thereof |
| 04/15/2004 | CA2500831A1 Treatment of autism and similar disorders |
| 04/15/2004 | CA2500830A1 Tumor targeting agents and uses thereof |
| 04/15/2004 | CA2500827A1 Tumor targeting agents and uses thereof |
| 04/15/2004 | CA2500731A1 Methods for controlling proliferation of cells |
| 04/15/2004 | CA2500687A1 Compositions and methods for the diagnosis and treatment of tumor |
| 04/15/2004 | CA2500673A1 Hbv mutations associated with reduced susceptibility to adefovir |
| 04/15/2004 | CA2500669A1 Products for regulating the degradation of collagen and methods for identifying same |
| 04/15/2004 | CA2500663A1 Enteric composition for the manufacture of soft capsule wall |
| 04/15/2004 | CA2500652A1 Diagnosis and monitoring of diseases |
| 04/15/2004 | CA2500626A1 Interferon variants with improved properties |
| 04/15/2004 | CA2500530A1 Therapeutic uses of .beta.-casein a2 and dietary supplement containing .beta.-casein a2 |
| 04/15/2004 | CA2500482A1 Method for diagnosing pancreatic cancer |
| 04/15/2004 | CA2500472A1 Genes and polypeptides relating to human pancreatic cancers |
| 04/15/2004 | CA2500470A1 Method for diagnosing chronic myeloid leukemia |
| 04/15/2004 | CA2500433A1 Recombinant intracellular pathogen immunogenic compositions and methods for use |
| 04/15/2004 | CA2500405A1 Genes and polypeptides relating to human myeloid leukemia |
| 04/15/2004 | CA2500401A1 Antigenic peptides |
| 04/15/2004 | CA2500389A1 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| 04/15/2004 | CA2500278A1 Pharmaceutical preparation for hearing impairment |
| 04/15/2004 | CA2500259A1 Potent inhibitor of hcv serine protease |
| 04/15/2004 | CA2500068A1 Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition in form of a kit |
| 04/15/2004 | CA2499837A1 Human papillomavirus polypeptides and immunogenic compositions |
| 04/15/2004 | CA2499483A1 Novel chemokine-like polypeptides |
| 04/15/2004 | CA2499458A1 Protein s protects the nervous system from injury |
| 04/15/2004 | CA2498854A1 Novel mhc ii associated peptides |
| 04/15/2004 | CA2498829A1 Use of protein tyrosine phosphatase inhibitors for prevention and/or treatment of cancer |
| 04/15/2004 | CA2498631A1 Use of a33 antigens and jam-it |
| 04/14/2004 | EP1408117A1 Glycoprotein and process for producing the same |
| 04/14/2004 | EP1408110A2 Oligonucleotide mediated specific cytokine induction and in vivo protection from infection |
| 04/14/2004 | EP1407785A1 Medicinal compositions |
| 04/14/2004 | EP1407783A1 Remedies for hernia |
| 04/14/2004 | EP1407781A1 Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents |
| 04/14/2004 | EP1407780A1 Pharmaceutically stable hemostatic compositions |
| 04/14/2004 | EP1407779A1 Use of ghrelin for treating low body weight and body fat in gastrectomized individuals |
| 04/14/2004 | EP1407752A1 Composite powders and skin preparations for external use containing the same |
| 04/14/2004 | EP1407677A2 Compositions comprising partly-hydrolized fish gelatin and use thereof |
| 04/14/2004 | EP1407276A2 Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension |
| 04/14/2004 | EP1407275A2 Use of transcription factor nak-1 or genes regulated by transcription factor nak-1 for the diagnosis and/or therapy of inflammatory and malignant diseases |
| 04/14/2004 | EP1407269A2 A method for diagnosing a person having multiple sclerosis |
| 04/14/2004 | EP1407267A2 Gel compositions |
| 04/14/2004 | EP1407049A2 Histone deacetylase and methods of use thereof |
| 04/14/2004 | EP1407044A2 Rna interference mediating small rna molecules |
| 04/14/2004 | EP1407030A2 Methods for large scale production of recombinant dna-derived tpa or k2s molecules |
| 04/14/2004 | EP1407023A2 Group b streptococcus antigens and corresponding dna fragments |
| 04/14/2004 | EP1407018A2 Human proteins, polynucleotides encoding them and methods of using the same |
| 04/14/2004 | EP1407015A2 Compositions and methods relating to breast specific genes and proteins |
| 04/14/2004 | EP1407013A1 Mutations in ion channels |
| 04/14/2004 | EP1407010A1 Regulation of human aminopeptidase n |
| 04/14/2004 | EP1406951A1 Keratin-based products and methods for their production |
| 04/14/2004 | EP1406930A2 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 04/14/2004 | EP1406929A2 Glycoprotein vi fusion proteins |
| 04/14/2004 | EP1406928A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 04/14/2004 | EP1406926A2 Novel neurotrophic factors |
| 04/14/2004 | EP1406922A2 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 04/14/2004 | EP1406921A1 Hypoglycaemic peptides and methods of use thereof |
| 04/14/2004 | EP1406916A2 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 04/14/2004 | EP1406915A2 Antisense modulation of transforming growth factor beta receptor ii expression |
| 04/14/2004 | EP1406879A1 Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents |
| 04/14/2004 | EP1406866A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 04/14/2004 | EP1406700A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 04/14/2004 | EP1406694A1 Electro-medical device for use with biologics |
| 04/14/2004 | EP1406678A1 Drug delivery matrices to enhance wound healing |
| 04/14/2004 | EP1406668A1 Composite oncolytic herpes virus vectors |
| 04/14/2004 | EP1406667A2 METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS |
| 04/14/2004 | EP1406665A2 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis |
| 04/14/2004 | EP1406657A1 A novel engineered superantigen for human therapy |
| 04/14/2004 | EP1406656A2 METHODS OF ADMINISTERING ANTI-TNF$g(a) ANTIBODIES |
| 04/14/2004 | EP1406655A2 A modulator of antiestrogen pharmacology |
| 04/14/2004 | EP1406652A2 Novel drug targets for arthritis |
| 04/14/2004 | EP1406651A2 Cosmetic or dermatological use of peptides for promoting adhesion between skin cells |
| 04/14/2004 | EP1406650A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 04/14/2004 | EP1406649A1 Use of substances with oxytocin activity against climacteric disorders |
| 04/14/2004 | EP1406648A1 The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| 04/14/2004 | EP1406647A1 Use of antimicrobial peptides as preservatives in ophthalmic preparations including solutions emulsions and suspensions |
| 04/14/2004 | EP1406646A1 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 04/14/2004 | EP1406645A2 Novel human transporter proteins and polynucleotides encoding the same |
| 04/14/2004 | EP1406644A2 Modified proteins, designer toxins, and methods of making thereof |
| 04/14/2004 | EP1406641A2 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
| 04/14/2004 | EP1406633A1 Enhanced drug delivery in transdermal systems |
| 04/14/2004 | EP1406630A1 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 04/14/2004 | EP1406629A1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump |
| 04/14/2004 | EP1406592A2 A salt/ion pair medicinal aerosol formulation |
| 04/14/2004 | EP1406573A2 Conditioned cell culture media and uses thereof |